Scarica l'app Stockscreener
54.26
0.84%
0.45
Dopo l'orario di chiusura:
56.25
1.99
+3.67%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BBIO Giù?
Forum
Previsione
Precedente Chiudi:
$53.81
Aprire:
$54.8
Volume 24 ore:
1.49M
Relative Volume:
0.64
Capitalizzazione di mercato:
$10.37B
Reddito:
$217.77M
Utile/perdita netta:
$-438.86M
Rapporto P/E:
-22.51
EPS:
-2.41
Flusso di cassa netto:
$-456.33M
1 W Prestazione:
-1.20%
1M Prestazione:
+7.13%
6M Prestazione:
+50.89%
1 anno Prestazione:
+124.49%
Intervallo 1D:
$54.23
$55.56
Intervallo di 1 settimana:
$52.75
$56.50
Portata 52W:
$21.72
$57.49
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Nome
Bridgebio Pharma Inc
Settore
Industria
Telefono
(650) 391-9740
Indirizzo
3160 PORTER DR., PALO ALTO, CA
Confronta BBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
54.26 | 10.29B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-14 | Iniziato | Jefferies | Buy |
| 2025-07-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Iniziato | Wolfe Research | Outperform |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-03 | Iniziato | Oppenheimer | Perform |
| 2024-09-04 | Iniziato | Piper Sandler | Overweight |
| 2024-03-21 | Ripresa | Raymond James | Outperform |
| 2024-01-31 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-07 | Iniziato | Citigroup | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Downgrade | Jefferies | Buy → Hold |
| 2023-04-19 | Iniziato | Evercore ISI | Outperform |
| 2023-02-06 | Iniziato | Cowen | Outperform |
| 2021-12-27 | Reiterato | Mizuho | Buy |
| 2021-12-27 | Reiterato | SVB Leerink | Outperform |
| 2021-09-10 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-03-22 | Reiterato | Goldman | Buy |
| 2021-02-22 | Ripresa | JP Morgan | Overweight |
| 2021-02-09 | Ripresa | Goldman | Buy |
| 2021-01-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Neutral |
| 2020-05-19 | Iniziato | BTIG Research | Buy |
| 2020-04-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-19 | Iniziato | Mizuho | Buy |
| 2019-07-26 | Iniziato | Raymond James | Outperform |
| 2019-07-22 | Iniziato | BMO Capital Markets | Outperform |
| 2019-07-22 | Iniziato | Goldman | Buy |
| 2019-07-22 | Iniziato | JP Morgan | Overweight |
| 2019-07-22 | Iniziato | Jefferies | Buy |
| 2019-07-22 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-22 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
Real time alert setup for BridgeBio Pharma Inc. performanceWeekly Trend Summary & Low Risk High Win Rate Stock Picks - newser.com
Will BridgeBio Pharma Inc. stock pay special dividendsEarnings Summary Report & Free AI Powered Buy and Sell Recommendations - newser.com
How BridgeBio Pharma Inc. (2CL) stock reacts to fiscal policiesExit Point & Low Drawdown Trading Strategies - newser.com
What indicators show strength in BridgeBio Pharma Inc.Fed Meeting & Real-Time Chart Pattern Alerts - newser.com
Why retail investors favor BridgeBio Pharma Inc. stock2025 Breakouts & Breakdowns & Low Risk Investment Opportunities - newser.com
BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week - The Manila Times
BridgeBio (NASDAQ: BBIO) to present FORTIFY interim topline Oct. 27; earnings Oct. 29 - Stock Titan
Is BridgeBio Pharma Inc. stock supported by strong fundamentalsJuly 2025 Selloffs & AI Enhanced Trading Alerts - newser.com
Will BridgeBio Pharma Inc. (2CL) stock outperform value peersQuarterly Trade Review & Entry and Exit Point Strategies - newser.com
What analysts say about BridgeBio Pharma Inc stockStop Loss Placement Tips & Small Investment Capital Tips - earlytimes.in
Sentiment analysis tools applied to BridgeBio Pharma Inc.2025 Support & Resistance & Fast Gain Swing Alerts - newser.com
BridgeBio Pharma Inc. stock trend outlook and recovery path2025 Technical Patterns & Entry and Exit Point Strategies - newser.com
Leading vs lagging indicators on BridgeBio Pharma Inc. performance2025 AllTime Highs & Daily Volume Surge Signals - newser.com
Long term hold vs stop loss in BridgeBio Pharma Inc.July 2025 Retail & Free High Return Stock Watch Alerts - newser.com
Using economic indicators to assess BridgeBio Pharma Inc. potentialChart Signals & Weekly High Return Stock Opportunities - newser.com
BridgeBio Pharma stock rating reiterated as Overweight by Wells Fargo - Investing.com Canada
BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights - MSN
Bridgebio Pharma Inc Azioni (BBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.11%
0.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):